Hesitancy to Receive the Booster Doses of COVID-19 Vaccine Among Cancer Patients in China: A Multicenter Cross-Sectional Survey — Four PLADs, China, 2022

Wang, Yuxiao; Zhang, Lei; Chen, Siyu; Lan, Xinquan; Song, Moxi; Su, Rila; Yang, Jianzhou; Wang, Zixin; Xu, Junjie

doi:10.46234/ccdcw2023.041

Cited by 10 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study further demonstrated that negative attitudes towards vaccines and perceived barriers were both associated with reduced acceptance of the second COVID-19 booster Dose. Similar results were found in immunocompromised cancer patients, which strengthened the necessity of vaccination among specific populations ( 34 , 35 ).…”

Section: Discussionsupporting

confidence: 79%

Willingness of people living with HIV to receive a second COVID-19 booster dose: a multicenter cross-sectional study in China

Lan,

Su,

Liang

et al. 2023

Front. Public Health

Self Cite

View full text Add to dashboard Cite

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has significantly affected the global population, with People Living with HIV (PLWH) being particularly vulnerable due to their compromised immune systems. Although vaccination is a crucial preventative measure against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, little is understood about the willingness of PLWH to receive a second COVID-19 booster dose and the factors that may influence this decision. This study investigates the willingness of PLWH in China to receive a second COVID-19 booster dose and its influencing factors, comparing these with a group of healthy individuals.MethodsA multicenter cross-sectional study was conducted across five Chinese cities, namely, Beijing, Tianjin, Zhengzhou, Hohhot, and Harbin. Participants were recruited through five community-based organizations. Data were collected via participant self-administered questionnaires included demographic information, willingness to receive a second COVID-19 booster dose, and knowledge about HIV and COVID-19 vaccination. Factors influencing vaccination willingness were identified using multivariable logistic regression analyzes.ResultsA total of 156 PLWH and 151 healthy individuals were included in the study. After adjusting for potential confounders, it was found that PLWH demonstrated a lower willingness to receive a second COVID-19 booster dose compared to healthy individuals (77.6% vs. 88.7%, p = 0.009). Lower willingness was associated with HIV positive status (Adjusted Odds Ratio [AOR]: 0.39, 95%CI: 0.20, 0.75), perceived barriers (AOR: 0.05, 95%CI: 0.01, 0.26), and perceived severity (AOR: 0.32, 95%CI: 0.12, 0.90).ConclusionPLWH in China demonstrated a lower willingness to receive a second COVID-19 booster dose compared to healthy individuals. The findings suggest that perceptions and understanding of the COVID-19 vaccination and its necessity for protection against SARS-CoV-2 could influence this willingness. Efforts should be made to strengthen and disseminate knowledge about HIV and COVID-19 vaccinations among this population. In addition, developing interventions and policies that target specific subgroups and address misconceptions about vaccination could be instrumental in improving vaccination rates among PLWH.

show abstract

Section: Discussionsupporting

confidence: 79%

Willingness of people living with HIV to receive a second COVID-19 booster dose: a multicenter cross-sectional study in China

Lan,

Su,

Liang

et al. 2023

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, recent studies showed that receiving a COVID-19 vaccine booster dose could significantly increase antibody titers among cancer patients and many countries have been recommending a third and a fourth dose of COVID-19 vaccine to cancer patients. 48–50 Therefore, the country may also consider introducing a COVID-19 vaccine booster dose to cancer patients. Many regions have already recommended a third and fourth dose of COVID-19 vaccines to immunodeficiency people, such as cancer patients, including in Hong Kong, China.…”

Section: Discussionmentioning

confidence: 99%

Concerns related to the interactions between COVID-19 vaccination and cancer/cancer treatment were barriers to complete primary vaccination series among Chinese cancer patients: A multicentre cross-sectional survey

Zhang

Yang

et al. 2023

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

COVID-19 vaccination is effective for cancer patients without safety concerns. However, COVID-19 vaccination hesitancy is common among cancer patients. This study investigated factors affecting primary COVID-19 vaccination series completion rate among cancer patients in China. A multicentre cross-sectional study was conducted in four Chinese cities in different geographic regions between May and June 2022. A total of 893 cancer inpatients provided written informed consent and completed the study. Logistic regression models were fitted. Among the participants, 58.8% completed the primary COVID-19 vaccination series. After adjusting for background characteristics, concerns about interactions between COVID-19 vaccination and cancers/cancer treatment (adjusted odds ratios [AOR]: 0.97, 95%CI: 0.94, 0.99) were associated with lower completion of primary vaccination series. In addition, perceived higher risk of COVID-19 infection comparing to people without cancers (AOR: 0.46, 95%CI: 0.24, 0.88), perceived a high chance of having severe consequences of COVID-19 infection (AOR: 0.68, 95%CI: 0.51, 0.91) were also associated with lower completion rate. Being suggested by significant others (AOR: 1.32, 95%CI: 1.23, 1.41) and perceived higher self-efficacy to receive COVID-19 vaccination (AOR: 1.48, 95%CI: 1.31, 1.67) were positively associated with the dependent variable. Completion rate of primary COVID-19 vaccination series was low among Chinese cancer patients. Given the large population size and their vulnerability, this group urgently needs to increase COVID-19 vaccination coverage. Removing concerns about interactions between COVID-19 vaccination and cancers, using fear appeal approach, involving significant others, and facilitating patients to make a plan to receive COVID-19 vaccination might be useful strategies.

show abstract

“…Hence, understanding the impact of booster doses on the immune response in PLWH is crucial for optimizing further vaccine strategies and ensuring adequate protection. Moreover, the acceptance of COVID‐19 vaccine is generally low while the risk of infection is high in people with immunodeficiency 25,26 . Of note, concerns for the performance of vaccine is an essential element to affect the willingness of booster doses vaccination.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, the acceptance of COVID-19 vaccine is generally low while the risk of infection is high in people with immunodeficiency. 25,26 Of note, concerns for the performance of vaccine is an essential element to affect the willingness of booster doses vaccination. Hence, understanding the immunogenicity and safety profiles for the vaccination among PLWH in the real-world would contribute to improving the coverage of vaccination.…”

Section: Introductionmentioning

confidence: 99%

Safety and immunogenicity of homologous prime‐boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study

Wang,

Lan,

Qiao

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

People living with HIV (PLWH) are particularly vulnerable to SARS‐CoV‐2. This multicentre prospective cohort study evaluated the long‐term immunogenicity and safety of a third homologous dose of Sinovac CoronaVac in PLWH in China. A total of 228 PLWH and 127 HIV‐negative controls were finally included and followed up for 6 months. Fewer participants reported mild or moderate adverse reactions, and no serious adverse events were observed. The median levels of neutralizing antibodies (nAbs) and immunoglobulin G against the receptor‐binding domain of the spike protein (S‐IgG) in PLWH (655.92 IU/mL, IQR: 175.76–1663.55; 206.83 IU/mL, IQR: 85.20–397.82) were comparable to those in control group (1067.16 IU/mL, IQR: 239.85–1670.83; 261.70 IU/mL, IQR: 77.13–400.75), and reached their peak at 4 weeks, exhibiting a delayed peak pattern compared to the 2‐week peak in control group. After then, the immune titres gradually decreased over time, but most participants still maintained positive seroconversion at the 6‐month mark. Multivariable generalized estimating equation analysis indicated that CD4+T cell count, HIV viral load, and antiretroviral therapy (ART) were independent factors strongly associated with immune response (each p < 0.05). We suggested that PLWH should maintain well‐controlled HIV status through ART and receive timely administration of the second booster dose for optimal protection.

show abstract

Hesitancy to Receive the Booster Doses of COVID-19 Vaccine Among Cancer Patients in China: A Multicenter Cross-Sectional Survey — Four PLADs, China, 2022

Cited by 10 publications

References 8 publications

Willingness of people living with HIV to receive a second COVID-19 booster dose: a multicenter cross-sectional study in China

Willingness of people living with HIV to receive a second COVID-19 booster dose: a multicenter cross-sectional study in China

Concerns related to the interactions between COVID-19 vaccination and cancer/cancer treatment were barriers to complete primary vaccination series among Chinese cancer patients: A multicentre cross-sectional survey

Safety and immunogenicity of homologous prime‐boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study

Contact Info

Product

Resources

About